Assess whether scientific advice should be sought before the next trial

Situation

Scientific advice should be sits with pediatric-plan strategist because a site-change that invalidates stability claims hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is CMC comparability package for a site change; write the Pharma & Life Sciences Clinical and Evidence Strategy option that extract can carry.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a site-change that invalidates stability claims.

Hypotheses to test

• A site-change that invalidates stability claims is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given CMC comparability package for a site change.
• A site-change that invalidates stability claims is the event in CMC comparability package for a site change that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after a site-change that invalidates stability claims, not a Clinical and Evidence Strategy program failure.
• CMC comparability package for a site change cannot decide scientific advice should be yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a site-change that invalidates stability claims.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a site-change that invalidates stability claims and write the one fact that would move scientific advice should be for pediatric-plan strategist.

Recommendation